Shuyi Ji

Shuyi Ji

Auto-generated profile, based on publicly available information

Shuyi Ji

Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
SJShuyi Ji
Shuyi Ji
LFLi Feng
Li Feng
ZFZile Fu
Zile Fu
GWGaohua Wu
Gaohua Wu
YWYing Cheng Wu
Ying Cheng Wu
QGQiang Gao
Qiang Gao
Organoid models have the potential to recapitulate the biological and pharmacotypic features of parental tumors. Nevertheless, integrative pharmaco-proteogenomics analysis for drug response features and biomarker investigation for precision therapy of patients with liver cancer are still lacking. We established a patient-derived liver cancer organoid biobank (LICOB) that comprehensively represents the histological and molecular characteristics of various liver cancer types as determined by multiomics profiling, including genomic, epigenomic, transcriptomic, and proteomic analysis. Proteogenomic profiling of LICOB identified proliferative and metabolic organoid subtypes linked to patient prognosis. High-throughput drug screening revealed distinct response patterns of each subtype that were associated with specific multiomics signatures. Through integrative analyses of LICOB pharmaco-proteogenomics data, we identified the molecular features associated with drug responses and predicted potential drug combinations for personalized patient treatment. The synergistic inhibition effect of mTOR inhibitor temsirolimus and the multitargeted tyrosine kinase inhibitor lenvatinib was validated in organoids and patient-derived xenografts models. We also provide a user-friendly web portal to help serve the biomedical research community. Our study is a rich resource for investigation of liver cancer biology and pharmacological dependencies and may help enable functional precision medicine.

24 July 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MZMao Zhang
Mao Zhang
YHYingying Huang
Yingying Huang
JPJiaomeng Pan
Jiaomeng Pan
CSChen Sang
Chen Sang
YLYoupei Lin
Youpei Lin
QGQiang Gao
Qiang Gao
KRAS mutations are causally linked to protumor inflammation and are identified as driving factors in tumorigenesis. Here, using multiomics data gathered from a large set of patients, we showed that KRAS mutation was associated with a specific landscape of alternative mRNA splicing that connected to myeloid inflammation in intrahepatic cholangiocarcinoma (iCCA). Then, we identified a negative feedback mechanism in which the upregulation of interleukin 1 receptor antagonist (IL1RN)-201/203 due to alternative splicing confers vital anti-inflammatory effects in KRAS-mutant iCCA. In KRAS-mutant iCCA mice, both IL1RN-201/203 upregulation and anakinra treatment ignited a significant antitumor immune response by altering neutrophil recruitment and phenotypes. Furthermore, anakinra treatment synergistically enhanced anti–PD-1 therapy to activate intratumoral GZMB+ CD8+ T cells in KRAS-mutant iCCA mice. Clinically, we found that high IL1RN-201/203 levels in patients with KRAS-mutant iCCA were significantly associated with superior response to anti–PD-1 immunotherapy. Significance: This work describes a novel inflammatory checkpoint mediated by IL1RN alternative splicing variants that may serve as a promising basis to develop therapeutic options for KRAS-mutant iCCA and other cancers. This article is featured in Selected Articles from This Issue, p. 2109

31 December 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JWJun Wang
Jun Wang
LLLong Liao
Long Liao
BMBeiping Miao
Beiping Miao
BYBo Yang
Bo Yang
BLBotai Li
Botai Li
CWCun Wang
Cun Wang
Ferroptosis, a unique form of iron-dependent cell death triggered by lipid peroxidation accumulation, holds great promise for cancer therapy. Despite the crucial role of GPX4 in regulating ferroptosis, our understanding of GPX4 protein regulation remains limited. Through FACS-based genome-wide CRISPR screening, we identified MALT1 as a regulator of GPX4 protein. Inhibition of MALT1 expression enhances GPX4 ubiquitination-mediated degradation by up-regulating the E3 ubiquitin ligase RC3H1. Using both rescue assays and functional genetic screening, we demonstrate that pharmacologically targeting MALT1 triggers ferroptosis in liver cancer cells. Moreover, we show that targeting MALT1 synergizes with sorafenib or regorafenib to induce ferroptosis across multiple cancer types. These findings elucidate the modulatory effects of the MALT1–RC3H1 axis on GPX4 stability, revealing a molecular mechanism that could be exploited to induce ferroptosis for cancer therapy.


12 December 2025
Verified
Other
Open access
MZMao Zhang
Mao Zhang
YHYingying Huang
Yingying Huang
JPJiaomeng Pan
Jiaomeng Pan
CSChen Sang
Chen Sang
YLYoupei Lin
Youpei Lin
QGQiang Gao
Qiang Gao
Supplementary Table S6. GO term and KEGG pathway information in Gzmb+ Cd8+ T cells.

16 September 2024
Verified
Other
Open access
MZMao Zhang
Mao Zhang
YHYingying Huang
Yingying Huang
JPJiaomeng Pan
Jiaomeng Pan
CSChen Sang
Chen Sang
YLYoupei Lin
Youpei Lin
QGQiang Gao
Qiang Gao
Supplementary Table S5. Top 200 genes for each T cell cluster obtained by wilcox test with the rank_genes_groups function in Scanpy.